# Abbreviations

| | |
|---|---|
| **ABS** | Antibiotic stewardship |
| **AGP** | Antimicrobial growth promoters |
| **AMR** | Antimicrobial resistance |
| **AMS** | Antimicrobial stewardship |
| **AMU** | Antimicrobial use |
| **ARB** | Antibiotic-resistant bacteria |
| **ARC** | Antibiotic Resistance Coalition |
| **ASP** | Antibiotic stewardship programme |
| **BARDA** | Biomedical Advanced Research and Development Authority |
| **BSI** | Bloodstream infection |
| **CARB-X** | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator |
| **CCCAS** | Clinician Champions in Comprehensive Antibiotic Stewardship |
| **CDC** | Centers for Disease Control |
| **CEWG** | Consultative Expert Working Group |
| **CRE** | Carbapenem-resistant Enterobacteriaceae |
| **CRP** | C-reactive Protein |
| **CSE** | Centre for Science and Environment |
| **CSF** | Cerebrospinal fluid |
| **DALY** | Disbility-adjusted life-year |
| **DDD** | Defined Daily Dose |
| **DG-RTD** | Directorate-General for Research and Innovation |
| **DP** | Delayed prescribing |
| **DRG** | Diagnosis-related group |
| **EARSS** | European Antibiotic Resistance Surveillance System |
| **EARS-NET** | European Antibiotic Resistance Surveillance Network |
| **EC** | Environmental cleaning |
| **ECDC** | European Centre for Disease Prevention and Control |

| | |
|---|---|
| **EDCTP** | European and Developing Countries Clinical Trial Partnership |
| **EEA** | European Economic Area |
| **EFPIA** | European Federation of Pharmaceutical Industries and Associations |
| **EFSA** | European Food Safety Authority |
| **EIB** | European Investment Bank |
| **EMA** | European Medicines Agency |
| **EPOC** | Effective Practice and Organisation of Care |
| **ESBL** | Extended spectrum beta-lactamase |
| **ETEC** | Enterotoxigenic *Escherichia coli* |
| **EU** | European Union |
| **FAO** | Food and Agricultural Organization |
| **FDA** | Food and Drug Administration |
| **G3REC** | Third-generation cephalosporin |
| **GAMRIF** | Global Antimicrobial Resistance Innovation Fund |
| **GARDP** | Global Antibiotic Research and Development Partnership |
| **GBS** | Group B Streptococcus |
| **GDP** | Gross Domestic Product |
| **GLASS** | Global Antimicrobial Resistance Surveillance System |
| **GP** | General practitioner |
| **GRACE INTRO** | Genomics to combat Resistance against Antibiotics for Community-acquired LRTI in Europe/INternet Training for Reducing antibiOtic use |
| **HAI** | Health care-associated infection/hospital-acquired infection |
| **HIV** | Human immunodeficiency virus |
| **HTA** | Health technology assessment |
| **ICU** | Intensive-care units |
| **ID** | Infectious diseases |
| **IMI** | Innovative Medicine's Initiative |
| **IPC** | Infection prevention and control |
| **JPIAMR** | Joint Programming Initiative on Antimicrobial Resistance |
| **KISS** | Krankenhaus-Infektions-Surveillance-System |
| **LMIC** | Low- and middle-income country |
| **LOS** | Length of stay |

| | |
|---|---|
| **LPAD** | Limited Population Antibacterial Drug |
| **mAb** | Monoclonal antibody |
| **MER** | Market entry rewards |
| **MRSA** | Methicillin-resistant *Staphylococcus aureus* |
| **MSF** | Médecins sans Frontières |
| **NHS** | National Health Service |
| **NIAID** | National Institute of Allergy and Infectious Diseases |
| **NIH** | National Institutes for Health |
| **NIHR** | National Institute for Health Research |
| **NRDC** | Natural Resources Defense Council |
| **OECD** | Organisation for Economic Co-operation and Development |
| **OIE** | World Organisation for Animal Health |
| **PCR** | Polymerase chain reaction |
| **PDP** | Product development partnerships |
| **PIRG** | Public Interest Research Group |
| **PMDA** | Pharmaceuticals and Medical Devices Agency |
| **POC** | Point of care |
| **POCT** | Point-of-care tests |
| **PPL** | Priority Pathogens List |
| **PPS** | Point prevalence surveys |
| **PRV** | Priority review vouchers |
| **QALY** | Quality-adjusted life-years |
| **QIDP** | Qualified Infectious Diseases Products |
| **R&D** | Research and development |
| **RCDC** | Research, condition, and disease categories |
| **RCT** | Randomized controlled trial |
| **RSV** | Respiratory syncytial virus |
| **RTI** | Respiratory tract infections |
| **SDM** | Shared decision-making |
| **SME** | Small and medium enterprises |
| **STEC** | Shiga toxin-producing *Escherichia coli* |
| **SWAB** | Working Party on Antibiotic Policy |
| **TATFAR** | Transatlantic Task Force on Antimicrobial Resistance |
| **TIPR** | Transferable intellectual property rights |
| **TPP** | Target Product Profile |
| **UNICEF** | United Nations Children's Fund |
| **UI** | uncertainty interval |
| **UPEC** | Uropathogenic *Escherichia coli* |

| | |
|---|---|
| **USDA** | US Department of Agriculture |
| **UTI** | Urinary tract infections |
| **VRE** | Vancomycin-resistant enterococci |
| **VTEC** | Verocytotoxin-producing *Escherichia coli* |
| **WHO** | World Health Organization |
| **WTO** | World Trade Organization |